Treatment of tyrosine kinase inhibitors on expression of Id2. (A) Western blot analysis of transduced 32Dcl3 cells treated with either imatinib or MLN518 using Id2 antibody. 32D/BCR-ABL cells treated with MLN518 or 32D/FLT3-ITD cells treated with imatinib were used as a negative control. The membrane was stripped and reblotted with RACK1 antibody as loading control. (B) Western blot analysis of transduced BaF3 cells treated with either imatinib or MLN518 using Id2 antibody. BaF3/BCR-ABL cells treated with MLN518 or BaF3/FLT3-ITD treated with imatinib were used as a negative control. The membrane was stripped and reblotted with RACK1 antibody as loading control.